ADCC
MCID: ADR054
MIFTS: 73

Adrenocortical Carcinoma, Hereditary (ADCC)

Categories: Cancer diseases, Cardiovascular diseases, Endocrine diseases, Genetic diseases, Nephrological diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Adrenocortical Carcinoma, Hereditary

MalaCards integrated aliases for Adrenocortical Carcinoma, Hereditary:

Name: Adrenocortical Carcinoma, Hereditary 57 29 6 40 73
Adrenocortical Carcinoma 41 12 76 53 59 75 29 6 44 15 73
Adrenal Cortical Carcinoma 57 41 12 13
Adrenocortical Carcinoma, Pediatric 29 6 73
Adcc 57 75
Malignant Neoplasm of Adrenal Cortex 73
Hereditary Adrenocortical Carcinoma 75
Pediatric Adrenocortical Carcinoma 75
Carcinoma of the Adrenal Cortex 12
Neoplasm of the Adrenal Cortex 29
Adrenal Cortical Neoplasm 6
Carcinoma Adrenocortical 55
Tumors of Adrenal Cortex 73
Adrenocortical Cancer 55
Acc 53

Characteristics:

Orphanet epidemiological data:

59
adrenocortical carcinoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood;

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
adrenocortical carcinoma, hereditary:
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Adrenocortical Carcinoma, Hereditary

NIH Rare Diseases : 53 Adrenocortical carcinoma is a rare cancer affecting the outside of the adrenal glands (adrenal cortex). These glands are on top of each kidney and are responsible for producing certain hormones and keeping blood pressure at normal levels. Adrenocortical carcinoma is relatively frequent in children compared to many other cancers, although the cancer may also affect adults. Girls are more often affected than boys. Symptoms of adrenocortical carcinoma may include pain in the abdomen, hypertension, weight gain, frequent urination and possibly deepening of the voice. These symptoms are due to the tumors causing excess secretion of hormones from the adrenal glands. Adrenocortical carcinoma may develop by chance alone, but at least 50% of the cancers are thought to be hereditary. There are a number of genes that have changes (mutations) that can cause an adrenocortical carcinoma, including TP53 and IGF2. There have been reports of both autosomal dominant inheritance and autosomal recessive inheritance. An adrenocortical carcinoma is diagnosed based on urine tests for abnormal levels of cortisol, the hormone released by the adrenal glands. Blood tests can also be conducted to measure levels of potassium and sodium in the blood. A CT scan or MRI may be used to search for a visible tumor in the adrenal cortex. Treatment options include surgical removal of the tumor, which is important to achieve a good long-term outlook. Chemotherapy, specifically a drug called mitotane, can be used to try to remove any remaining cancer after surgery. 

MalaCards based summary : Adrenocortical Carcinoma, Hereditary, also known as adrenocortical carcinoma, is related to adrenal carcinoma and adenoid cystic carcinoma, and has symptoms including fever and flank pain. An important gene associated with Adrenocortical Carcinoma, Hereditary is TP53 (Tumor Protein P53), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Development Angiotensin activation of ERK. The drugs Abraxane and Arranon have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal cortex and lung, and related phenotypes are diabetes mellitus and hypertension

Disease Ontology : 12 An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has material basis in abnormally proliferating cells derives from epithelial cells.

OMIM : 57 Adrenocortical carcinoma (ADCC) is a rare but aggressive childhood tumor, representing about 0.4% of childhood tumors, with a high incidence of associated tumors. ADCC occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome (130650) and is a component tumor in Li-Fraumeni syndrome (LFS; 151623). (202300)

UniProtKB/Swiss-Prot : 75 Adrenocortical carcinoma: A malignant neoplasm of the adrenal cortex and a rare childhood tumor. It occurs with increased frequency in patients with Beckwith-Wiedemann syndrome and Li-Fraumeni syndrome.

Wikipedia : 76 Adrenocortical carcinoma (ACC, adrenal cortical carcinoma, adrenal cortical cancer, adrenal cortex... more...

Related Diseases for Adrenocortical Carcinoma, Hereditary

Diseases related to Adrenocortical Carcinoma, Hereditary via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 259)
# Related Disease Score Top Affiliating Genes
1 adrenal carcinoma 33.3 CYP11A1 CYP11B2 CYP17A1 IGF2 NR5A1
2 adenoid cystic carcinoma 32.9 CHEK2 CTNNB1 PIK3CA TP53
3 li-fraumeni syndrome 2 32.7 CHEK2 TP53
4 leukemia, chronic lymphocytic 2 30.3 BRAF NRAS TP53
5 adrenal cortical adenoma 30.3 CYP11A1 CYP17A1 MC2R NR5A1 PRKAR1A
6 neuroblastoma 30.2 CTNNB1 H19 MIR184 NRAS PIK3CA TP53
7 thyroid cancer 30.2 BRAF CTNNB1 GNAS H19 NRAS PIK3CA
8 carcinosarcoma 30.1 CTNNB1 PIK3CA TP53
9 adenocarcinoma 30.1 BRAF CTNNB1 GNAS H19 PIK3CA TP53
10 adenoma 30.1 BRAF CTNNB1 CYP11B2 GNAS TP53
11 hemihyperplasia, isolated 30.0 H19 IGF2
12 squamous cell carcinoma 30.0 BRAF CHEK2 CTNNB1 H19 PIK3CA TP53
13 sarcoma 30.0 BRAF CHEK2 CTNNB1 PIK3CA TP53
14 hepatocellular carcinoma 30.0 CTNNB1 GNAS H19 IGF2 MIR195 MIR214
15 conn's syndrome 30.0 CYP11A1 CYP11B2 CYP17A1 GNAS MC2R PRKAR1A
16 lung cancer susceptibility 3 30.0 BRAF CTNNB1 GNAS H19 NRAS PIK3CA
17 lung cancer 29.9 BRAF CHEK2 H19 MIR195 MIR214 MIR511
18 squamous cell carcinoma, head and neck 29.9 BRAF CTNNB1 GNAS H19 MIR195 MIR214
19 ovarian cancer 29.8 BRAF CHEK2 CTNNB1 H19 MIR184 MIR195
20 breast cancer 29.8 BRAF CHEK2 CTNNB1 CYP17A1 GNAS H19
21 colorectal cancer 29.7 BRAF CHEK2 CTNNB1 GNAS H19 IGF2
22 adrenocortical carcinoma with pure aldosterone hypersecretion 12.3
23 corpus callosum, agenesis of 11.8
24 aplasia cutis congenita 11.8
25 aplasia cutis congenita, nonsyndromic 11.7
26 li-fraumeni syndrome 11.7
27 hereditary motor and sensory neuropathy with agenesis of the corpus callosum 11.3
28 corpus callosum, agenesis of, with abnormal genitalia 11.3
29 aplasia cutis congenita with intestinal lymphangiectasia 11.1
30 agenesis of the corpus callosum with peripheral neuropathy 11.1
31 aplasia cutis congenita of limbs recessive 11.1
32 epidermolysis bullosa junctionalis with pyloric atresia 11.0
33 aicardi syndrome 11.0
34 acetyl-coa carboxylase deficiency 11.0
35 vici syndrome 11.0
36 corpus callosum, partial agenesis of, x-linked 11.0
37 adams-oliver syndrome 2 11.0
38 corpus callosum agenesis-intellectual disability-coloboma-micrognathia syndrome 11.0
39 ceruminous adenocarcinoma 11.0
40 x-linked lissencephaly with abnormal genitalia 11.0
41 acinar cell carcinoma of pancreas 11.0
42 esterase c 10.7
43 myocardial infarction 10.5
44 heart disease 10.5
45 arteries, anomalies of 10.5
46 cardiac conduction defect 10.4
47 atrial fibrillation 10.4
48 ischemic heart disease 10.4
49 nevus of ota 10.4 BRAF TP53
50 silver-russell syndrome due to an imprinting defect of 11p15 10.4 H19 IGF2

Graphical network of the top 20 diseases related to Adrenocortical Carcinoma, Hereditary:



Diseases related to Adrenocortical Carcinoma, Hereditary

Symptoms & Phenotypes for Adrenocortical Carcinoma, Hereditary

Symptoms via clinical synopsis from OMIM:

57
Oncology:
adrenocortical carcinoma

Endocrine:
virilism


Clinical features from OMIM:

202300

Human phenotypes related to Adrenocortical Carcinoma, Hereditary:

59 32 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0000819
2 hypertension 59 32 frequent (33%) Frequent (79-30%) HP:0000822
3 hyperhidrosis 59 32 frequent (33%) Frequent (79-30%) HP:0000975
4 muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0001324
5 hypokalemia 59 32 frequent (33%) Frequent (79-30%) HP:0002900
6 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
7 lung adenocarcinoma 59 32 frequent (33%) Frequent (79-30%) HP:0030078
8 irritability 59 32 frequent (33%) Frequent (79-30%) HP:0000737
9 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
10 anxiety 59 32 frequent (33%) Frequent (79-30%) HP:0000739
11 striae distensae 59 32 frequent (33%) Frequent (79-30%) HP:0001065
12 hyperaldosteronism 59 32 frequent (33%) Frequent (79-30%) HP:0000859
13 adrenocortical carcinoma 59 32 obligate (100%) Obligate (100%) HP:0006744
14 increased urinary cortisol level 59 32 frequent (33%) Frequent (79-30%) HP:0012030
15 increased body weight 59 32 frequent (33%) Frequent (79-30%) HP:0004324
16 abnormality of reproductive system physiology 59 32 frequent (33%) Frequent (79-30%) HP:0000080
17 adrenocorticotropic hormone deficiency 59 32 frequent (33%) Frequent (79-30%) HP:0011748
18 palpitations 59 32 frequent (33%) Frequent (79-30%) HP:0001962
19 hypertrichosis 59 32 frequent (33%) Frequent (79-30%) HP:0000998
20 increased serum estradiol 59 32 frequent (33%) Frequent (79-30%) HP:0025134
21 panic attack 59 32 frequent (33%) Frequent (79-30%) HP:0025269
22 paradoxical increased cortisol secretion on dexamethasone suppression test 59 32 frequent (33%) Frequent (79-30%) HP:0003466
23 increased serum androstenedione 59 32 frequent (33%) Frequent (79-30%) HP:0025380
24 elevated serum 11-deoxycortisol 59 32 frequent (33%) Frequent (79-30%) HP:0025436
25 abnormal serum dehydroepiandrosterone level 59 32 frequent (33%) Frequent (79-30%) HP:0500022
26 abnormality of metabolism/homeostasis 59 Frequent (79-30%)
27 abnormality of urine homeostasis 59 Occasional (29-5%)
28 increased circulating cortisol level 59 Frequent (79-30%)
29 increased circulating androgen level 59 Frequent (79-30%)

UMLS symptoms related to Adrenocortical Carcinoma, Hereditary:


fever, flank pain

MGI Mouse Phenotypes related to Adrenocortical Carcinoma, Hereditary:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 BRAF CTNNB1 CYP11A1 CYP17A1 GNAS IGF2
2 cardiovascular system MP:0005385 10.37 BRAF CTNNB1 CYP11A1 CYP11B2 GNAS IGF2
3 endocrine/exocrine gland MP:0005379 10.37 BRAF CHEK2 CTNNB1 CYP11A1 CYP11B2 GNAS
4 homeostasis/metabolism MP:0005376 10.37 BRAF CHEK2 CTNNB1 CYP11A1 CYP11B2 CYP17A1
5 cellular MP:0005384 10.36 BRAF CHEK2 CTNNB1 CYP11A1 CYP17A1 GNAS
6 growth/size/body region MP:0005378 10.36 BRAF CTNNB1 CYP11A1 CYP11B2 CYP17A1 GNAS
7 immune system MP:0005387 10.29 BRAF CHEK2 CTNNB1 CYP11A1 CYP11B2 GNAS
8 hematopoietic system MP:0005397 10.28 BRAF CHEK2 CTNNB1 CYP11A1 CYP11B2 GNAS
9 mortality/aging MP:0010768 10.27 BRAF CHEK2 CTNNB1 CYP11A1 CYP17A1 GNAS
10 adipose tissue MP:0005375 10.21 BRAF CYP11B2 CYP17A1 GNAS MC2R PIK3CA
11 embryo MP:0005380 10.17 BRAF CTNNB1 IGF2 NR5A1 NRAS PIK3CA
12 liver/biliary system MP:0005370 10.13 BRAF CTNNB1 CYP11A1 CYP11B2 GNAS IGF2
13 craniofacial MP:0005382 10.12 BRAF CTNNB1 GNAS IGF2 NRAS PRKAR1A
14 nervous system MP:0003631 10.11 BRAF CHEK2 CTNNB1 CYP11A1 CYP11B2 GNAS
15 integument MP:0010771 10.1 BRAF CTNNB1 GNAS IGF2 NRAS PIK3CA
16 muscle MP:0005369 10.03 BRAF CTNNB1 CYP11A1 GNAS IGF2 PIK3CA
17 neoplasm MP:0002006 10.01 BRAF CHEK2 CTNNB1 GNAS NRAS PIK3CA
18 reproductive system MP:0005389 9.85 BRAF CTNNB1 CYP11A1 CYP11B2 CYP17A1 IGF2
19 renal/urinary system MP:0005367 9.8 BRAF CTNNB1 CYP11B2 CYP17A1 GNAS IGF2
20 pigmentation MP:0001186 9.72 BRAF CTNNB1 NRAS PRKAR1A TP53
21 skeleton MP:0005390 9.61 BRAF CTNNB1 CYP17A1 GNAS IGF2 NRAS
22 vision/eye MP:0005391 9.23 BRAF CTNNB1 CYP11A1 IGF2 NRAS PIK3CA

Drugs & Therapeutics for Adrenocortical Carcinoma, Hereditary

FDA approved drugs:

(show top 50) (show all 77)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
3
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
4
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
5
Blincyto 18 49 BLINATUMOMAB Amgen December 2014
6
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
7
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
8
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
9
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
10
Cometriq 18 49 CABOZANTINIB S-MALATE Exelixis November 2012
11
Cyramza 18 49 RAMUCIRUMAB Eli Lilly April 2014
12
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
13
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
14
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
15
Erivedge 18 49 VISMODEGIB Genentech January 2012
16
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
17
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
18
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
19
Gilotrif 18 49 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
20
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
21
Ibrance 18 49 PALBOCICLIB Pfizer February 2015
22
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
23
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
24
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
25
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
26
Kadcyla 18 49 ADO-TRASTUZUMAB EMTANSINE Genentech February 2013
27
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
28
Kyprolis 18 49 CARFILZOMIB Onyx Pharmaceuticals July 2012
29
Lazanda 18 FENTANYL CITRATE Archimedes June 2011
30
Lenvima 18 49 LENVATINIB MESYLATE Eisai February 2015
31
Leukine 18 SARGRAMOSTIM Immunex on November 24, 1995/ November 1996
32
Lynparza 18 49 OLAPARIB AstraZeneca December 2014
33
Mekinist 18 49 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
34
Miraluma Test 18 TECHNETIUM TC-99M SESTAMIBI KIT DuPont Merck Pharmaceutical Company May 1997
35
Odomzo 18 49 SONIDEGIB PHOSPHATE Novartis Jul-15
36
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
37
Perjeta 18 49 PERTUZUMAB Genentech June 2012
38
Premarin 18 ESTROGENS CONJUGATED Wyeth July of 2003
39
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
40
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
41
Stivarga 18 49 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
42
Subsys 18 FENTANYL Insys Therapeutics January of 2012
43
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
44
Synercid I.V. 18 DALFOPRISTIN; QUINUPRISTIN QUINUPRISTIN; DALFOPRISTIN Rhone Poulenc Rorer September 1999
45
Synribo 18 49 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
46
Tafinlar 18 49 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
47
Tarceva 18 49 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
48
Tasigna 18 49 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
49
Torisel 18 49 TEMSIROLIMUS Wyeth May 2007
50
Trelstar Depot/ Trelstar LA 18 TRIPTORELIN PAMOATE Debio Rechereche Pharmaceutique, Target Research Associates/ Debiopharm June 2000/ June 2001

Search Clinical Trials , NIH Clinical Center for Adrenocortical Carcinoma, Hereditary

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: adrenocortical carcinoma

Genetic Tests for Adrenocortical Carcinoma, Hereditary

Genetic tests related to Adrenocortical Carcinoma, Hereditary:

# Genetic test Affiliating Genes
1 Adrenocortical Carcinoma, Hereditary 29 TP53
2 Adrenocortical Carcinoma 29
3 Adrenocortical Carcinoma, Pediatric 29
4 Neoplasm of the Adrenal Cortex 29

Anatomical Context for Adrenocortical Carcinoma, Hereditary

MalaCards organs/tissues related to Adrenocortical Carcinoma, Hereditary:

41
Cortex, Adrenal Cortex, Lung, Testes, T Cells, Endothelial, Adrenal Gland

Publications for Adrenocortical Carcinoma, Hereditary

Articles related to Adrenocortical Carcinoma, Hereditary:

(show top 50) (show all 1006)
# Title Authors Year
1
Co-culture of H295R Adrenocortical Carcinoma and BeWo Choriocarcinoma Cells to Study Feto-placental Interactions: Focus on Estrogen Biosynthesis. ( 29197012 )
2018
2
Adrenocortical carcinoma characterized by gynecomastia: A case report. ( 29403152 )
2018
3
Synchronous adrenocortical carcinoma and ovarian malignant mixed germ cell tumor: A case report and literature review. ( 29768344 )
2018
4
Adrenocortical Carcinoma Presenting as Reversible Dilated Cardiomyopathy. ( 30505399 )
2018
5
High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma. ( 29192018 )
2018
6
Incidentally detected adrenocortical carcinoma in familial adenomatous polyposis: an unusual presentation of a hereditary cancer syndrome. ( 30181409 )
2018
7
The coexistence of Cushing syndrome and gynecomastia as the manifestations of adrenocortical carcinoma. ( 30527206 )
2018
8
Composite Adrenocortical Carcinoma and Neuroblastoma in an Infant With a TP53 Germline Mutation: A Case Report and Literature Review. ( 29746440 )
2018
9
Identification of Five Genes as a Potential Biomarker for Predicting Progress and Prognosis in Adrenocortical Carcinoma. ( 30519354 )
2018
10
ASO Author Reflections: PTTG1 Protein Expression in Adrenocortical Carcinoma. ( 30519761 )
2018
11
A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. ( 29164414 )
2018
12
Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. ( 29212777 )
2018
13
STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro. ( 29214451 )
2018
14
Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma. ( 29218429 )
2018
15
Images: Port site recurrence on followup imaging after adrenalectomy for adrenocortical carcinoma - first indicator of carcinomatosis. ( 29283086 )
2018
16
Laparoscopic Versus Open Adrenalectomy for Localized/Locally Advanced Primary Adrenocortical Carcinoma (ENSAT I-III) in Adults: Is Margin-Free Resection the Key Surgical Factor that Dictates Outcome? A Review of the Literature. ( 29319399 )
2018
17
The impact of patient-, disease-, and treatment-related factors on survival in patients with adrenocortical carcinoma. ( 29319480 )
2018
18
Delayed presentation of a virilising, pure testosterone-secreting adrenocortical carcinoma with coexistent composite myelolipoma and a venous thrombus extending to the heart. ( 29367375 )
2018
19
Development of new preclinical models to advance adrenocortical carcinoma research. ( 29371329 )
2018
20
Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo. ( 29411361 )
2018
21
BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy. ( 29428231 )
2018
22
Adrenocortical carcinoma: where we stand. ( 29442479 )
2018
23
Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI. ( 29444511 )
2018
24
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. ( 29452402 )
2018
25
BILATERAL ADRENOCORTICAL CARCINOMA: CASE REPORT AND REVIEW OF LITERATURE. ( 29461221 )
2018
26
Yttrium-90 microsphere selective internal radiation therapy for liver metastases following systemic chemotherapy and surgical resection for metastatic adrenocortical carcinoma. ( 29468134 )
2018
27
The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. ( 29474877 )
2018
28
MANAGEMENT OF ENDOCRINE DISEASE: Adrenocortical carcinoma: differentiating the good from the poor prognosis tumors. ( 29475877 )
2018
29
Impact of Micro- and Macroscopically Positive Surgical Margins on Survival after Resection of Adrenocortical Carcinoma. ( 29500765 )
2018
30
A case of adrenocortical carcinoma accompanying secondary acute adrenal hypofunction postoperation. ( 29506536 )
2018
31
The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells. ( 29507530 )
2018
32
Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation. ( 29532999 )
2018
33
Prostate-Specific Membrane Antigen Expression in Adrenocortical Carcinoma on 68Ga-Prostate-Specific Membrane Antigen PET/CT. ( 29578871 )
2018
34
Open adrenalectomy versus laparoscopic adrenalectomy for adrenocortical carcinoma: a retrospective comparative study on short-term oncologic prognosis. ( 29606881 )
2018
35
A rare cause of dysregulated metabolic syndrome: cortisol-producing adrenocortical carcinoma. ( 29667589 )
2018
36
β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion. ( 29670378 )
2018
37
Prognostic factors in adrenocortical carcinoma: data from a large Polish series. ( 29726479 )
2018
38
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. ( 29734384 )
2018
39
Immunohistochemical expression of glypican-3 in adrenocortical carcinoma: A potential cause of diagnostic pitfalls. ( 29748062 )
2018
40
Adjuvant Radiation is Associated with Improved Survival for Select Patients with Non-metastatic Adrenocortical Carcinoma. ( 29748889 )
2018
41
Bone metastasis located on foot as a clinical presentation of an adrenocortical carcinoma. ( 29752041 )
2018
42
Adrenocortical Carcinoma with Hypercortisolism. ( 29754640 )
2018
43
MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma. ( 29773584 )
2018
44
Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. ( 29790920 )
2018
45
Adrenocortical Carcinoma in Children: A Clinicopathological Analysis of 41 Patients at the Mayo Clinic from 1950 to 2017. ( 29804118 )
2018
46
Nicotinamide Nucleotide Transhydrogenase as a Novel Treatment Target in Adrenocortical Carcinoma. ( 29850793 )
2018
47
Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. ( 29868977 )
2018
48
SLC12A7 alters adrenocortical carcinoma cell adhesion properties to promote an aggressive invasive behavior. ( 29884238 )
2018
49
TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma. ( 29956721 )
2018
50
Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( 29967789 )
2018

Variations for Adrenocortical Carcinoma, Hereditary

ClinVar genetic disease variations for Adrenocortical Carcinoma, Hereditary:

6 (show top 50) (show all 141)
# Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.4(CHEK2): c.470T> C (p.Ile157Thr) single nucleotide variant risk factor rs17879961 GRCh37 Chromosome 22, 29121087: 29121087
2 CHEK2 NM_007194.4(CHEK2): c.470T> C (p.Ile157Thr) single nucleotide variant risk factor rs17879961 GRCh38 Chromosome 22, 28725099: 28725099
3 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
4 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
5 TP53 NM_000546.5(TP53): c.1010G> A (p.Arg337His) single nucleotide variant Pathogenic rs121912664 GRCh37 Chromosome 17, 7574017: 7574017
6 TP53 NM_000546.5(TP53): c.1010G> A (p.Arg337His) single nucleotide variant Pathogenic rs121912664 GRCh38 Chromosome 17, 7670699: 7670699
7 TP53 NM_000546.5(TP53): c.854A> T (p.Glu285Val) single nucleotide variant Pathogenic rs121912667 GRCh37 Chromosome 17, 7577084: 7577084
8 TP53 NM_000546.5(TP53): c.854A> T (p.Glu285Val) single nucleotide variant Pathogenic rs121912667 GRCh38 Chromosome 17, 7673766: 7673766
9 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
10 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
11 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
12 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
13 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
14 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
15 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
16 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh38 Chromosome 7, 140753354: 140753354
17 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
18 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh38 Chromosome 20, 58909365: 58909365
19 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
20 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh38 Chromosome 20, 58909366: 58909366
21 CTNNB1 NM_001904.3(CTNNB1): c.121A> G (p.Thr41Ala) single nucleotide variant Conflicting interpretations of pathogenicity, other rs121913412 GRCh37 Chromosome 3, 41266124: 41266124
22 CTNNB1 NM_001904.3(CTNNB1): c.121A> G (p.Thr41Ala) single nucleotide variant Conflicting interpretations of pathogenicity, other rs121913412 GRCh38 Chromosome 3, 41224633: 41224633
23 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
24 CTNNB1 NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val) single nucleotide variant Conflicting interpretations of pathogenicity rs28931589 GRCh38 Chromosome 3, 41224613: 41224613
25 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
26 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh38 Chromosome 3, 41224610: 41224610
27 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
28 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh38 Chromosome 3, 41224613: 41224613
29 CTNNB1 NM_001904.3(CTNNB1): c.122C> T (p.Thr41Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913413 GRCh37 Chromosome 3, 41266125: 41266125
30 CTNNB1 NM_001904.3(CTNNB1): c.122C> T (p.Thr41Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913413 GRCh38 Chromosome 3, 41224634: 41224634
31 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
32 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh38 Chromosome 3, 41224646: 41224646
33 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh37 Chromosome 3, 41266136: 41266136
34 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh38 Chromosome 3, 41224645: 41224645
35 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
36 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 GRCh38 Chromosome 3, 179234296: 179234296
37 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
38 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Likely pathogenic rs397516896 GRCh38 Chromosome 7, 140753355: 140753355
39 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
40 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh38 Chromosome 1, 114713909: 114713909
41 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 NCBI36 Chromosome 1, 115058053: 115058053
42 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
43 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh38 Chromosome 17, 7674262: 7674262
44 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
45 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
46 TP53 NM_000546.5(TP53): c.404G> A (p.Cys135Tyr) single nucleotide variant Likely pathogenic rs587781991 GRCh37 Chromosome 17, 7578526: 7578526
47 TP53 NM_000546.5(TP53): c.404G> A (p.Cys135Tyr) single nucleotide variant Likely pathogenic rs587781991 GRCh38 Chromosome 17, 7675208: 7675208
48 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh37 Chromosome 17, 7579313: 7579313
49 TP53 NM_000546.5(TP53): c.374C> T (p.Thr125Met) single nucleotide variant Conflicting interpretations of pathogenicity rs786201057 GRCh38 Chromosome 17, 7675995: 7675995
50 GNAS NM_000516.5(GNAS): c.602G> T (p.Arg201Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421

Cosmic variations for Adrenocortical Carcinoma, Hereditary:

9 (show top 50) (show all 243)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM43931 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.523C>A p.R175S 17:7675089-7675089 9
2 COSM11286 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1015G>T p.E339* 17:7670694-7670694 9
3 COSM10801 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.404G>A p.C135Y 17:7675208-7675208 9
4 COSM44175 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.644G>C p.S215T 17:7674887-7674887 9
5 COSM4445248 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1132G>T p.E378* 11:64805688-64805688 9
6 COSM4445247 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.812G>C p.G271A 11:64807191-64807191 9
7 COSM4445249 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.808C>A p.L270M 11:64807195-64807195 9
8 COSM4445246 MED12 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.4857G>T p.K1619N 23:71134842-71134842 9
9 COSM5669 CTNNB1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.98C>T p.S33F 3:41224610-41224610 9
10 COSM4440759 APC adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.232G>T p.D78Y 5:112767200-112767200 9
11 COSM6972839 ZRSR2 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.347G>T p.R116M 23:15804145-15804145 8
12 COSM6918517 YAP1 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1123A>C p.I375L 11:102229710-102229710 8
13 COSM6975028 XPO1 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.775A>G p.M259V 2:61496992-61496992 8
14 COSM6972832 TSC2 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.4632G>T p.K1544N 16:2085292-2085292 8
15 COSM10662 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 8
16 COSM44083 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1036G>T p.E346* 17:7670673-7670673 8
17 COSM10645 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.527G>T p.C176F 17:7675085-7675085 8
18 COSM11066 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.578A>T p.H193L 17:7674953-7674953 8
19 COSM43650 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.638G>T p.R213L 17:7674893-7674893 8
20 COSM11245 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.430C>T p.Q144* 17:7675182-7675182 8
21 COSM107991 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1051A>G p.K351E 17:7670658-7670658 8
22 COSM6815 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.461G>T p.G154V 17:7675151-7675151 8
23 COSM44091 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.746G>A p.R249K 17:7674217-7674217 8
24 COSM44094 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.716A>G p.N239S 17:7674247-7674247 8
25 COSM10738 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.542G>A p.R181H 17:7675070-7675070 8
26 COSM10911 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.847C>T p.R283C 17:7673773-7673773 8
27 COSM11071 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1009C>T p.R337C 17:7670700-7670700 8
28 COSM44571 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.581T>G p.L194R 17:7674950-7674950 8
29 COSM5706561 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.995T>G p.I332S 17:7670714-7670714 8
30 COSM43963 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.396G>C p.K132N 17:7675216-7675216 8
31 COSM10726 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.856G>A p.E286K 17:7673764-7673764 8
32 COSM10648 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 8
33 COSM43755 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.833C>A p.P278H 17:7673787-7673787 8
34 COSM307331 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.973G>T p.G325* 17:7673555-7673555 8
35 COSM10659 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.817C>T p.R273C 17:7673803-7673803 8
36 COSM10790 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.455C>T p.P152L 17:7675157-7675157 8
37 COSM11524 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.730G>T p.G244C 17:7674233-7674233 8
38 COSM44081 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.1073A>T p.E358V 17:7670636-7670636 8
39 COSM44623 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.487T>A p.Y163N 17:7675125-7675125 8
40 COSM44288 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.452C>T p.P151L 17:7675160-7675160 8
41 COSM10722 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.853G>A p.E285K 17:7673767-7673767 8
42 COSM10725 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.701A>G p.Y234C 17:7674262-7674262 8
43 COSM44570 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.332T>G p.L111R 17:7676037-7676037 8
44 COSM44816 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.667C>T p.P223S 17:7674864-7674864 8
45 COSM6919580 TNFAIP3 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.484C>T p.R162W 6:137875033-137875033 8
46 COSM6972835 SPOP adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.244G>T p.D82Y 17:49619342-49619342 8
47 COSM6972842 SH2D1A adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.262C>A p.Q88K 23:124370236-124370236 8
48 COSM6934645 SETD2 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.3362C>G p.S1121C 3:47103392-47103392 8
49 COSM6972818 SETD2 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.313G>T p.E105* 3:47122814-47122814 8
50 COSM6972816 SETD2 adrenal gland,adrenal gland,adrenal cortical carcinoma,NS c.4252G>T p.E1418* 3:47084019-47084019 8

Copy number variations for Adrenocortical Carcinoma, Hereditary from CNVD:

7 (show all 23)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39293 10 11285212 16864223 Deletion Adrenocortical carcinoma
2 41923 10 26030462 27568983 Deletion Adrenocortical carcinoma
3 69267 12 54496959 54887816 Amplification Adrenocortical carcinoma
4 105388 16 79195214 80590034 Amplification Adrenocortical carcinoma
5 105796 16 82774218 84680399 Amplification Adrenocortical carcinoma
6 106027 16 85171711 86599633 Amplification Adrenocortical carcinoma
7 106330 16 87455812 88254372 Amplification Adrenocortical carcinoma
8 110643 17 33805634 34663603 Deletion Adrenocortical carcinoma
9 125811 19 15352798 16118051 Deletion Adrenocortical carcinoma
10 129302 19 45108448 45718366 Deletion Adrenocortical carcinoma
11 130528 19 49537470 50323207 Deletion Adrenocortical carcinoma
12 130657 19 50358143 53057498 Deletion Adrenocortical carcinoma
13 131131 19 53210832 53917176 Deletion Adrenocortical carcinoma
14 169573 3 142987765 144031265 Deletion Adrenocortical carcinoma
15 176088 3 46534671 47516603 Deletion Adrenocortical carcinoma
16 176572 3 49687490 50219610 Deletion Adrenocortical carcinoma
17 177057 3 52432656 53876467 Deletion Adrenocortical carcinoma
18 216378 6 91152410 95641352 Deletion Adrenocortical carcinoma
19 222196 7 150275058 151470304 Amplification Adrenocortical carcinoma
20 235763 8 144753570 146201712 Deletion Adrenocortical carcinoma
21 237149 8 21408650 22539377 Deletion Adrenocortical carcinoma
22 238033 8 29147511 31607545 Deletion Adrenocortical carcinoma
23 239018 8 36481039 39128088 Deletion Adrenocortical carcinoma

Expression for Adrenocortical Carcinoma, Hereditary

Search GEO for disease gene expression data for Adrenocortical Carcinoma, Hereditary.

Pathways for Adrenocortical Carcinoma, Hereditary

Pathways related to Adrenocortical Carcinoma, Hereditary according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.96 CTNNB1 GNAS IGF2 NRAS PIK3CA TP53
2
Show member pathways
12.89 BRAF GNAS NRAS PIK3CA PRKAR1A TP53
3
Show member pathways
12.85 BRAF GNAS NRAS PIK3CA PRKAR1A
4
Show member pathways
12.84 BRAF CTNNB1 NRAS PIK3CA TP53
5
Show member pathways
12.81 BRAF GNAS IGF2 NRAS PIK3CA PRKAR1A
6
Show member pathways
12.78 BRAF CTNNB1 GNAS NRAS PRKAR1A
7
Show member pathways
12.74 BRAF GNAS NRAS PIK3CA TP53
8
Show member pathways
12.68 BRAF CTNNB1 NRAS PIK3CA TP53
9
Show member pathways
12.65 CYP11A1 CYP11B2 CYP17A1 GNAS MC2R NR5A1
10
Show member pathways
12.62 BRAF CTNNB1 IGF2 NRAS PIK3CA TP53
11 12.59 BRAF CTNNB1 GNAS IGF2 NRAS PIK3CA
12
Show member pathways
12.52 BRAF CTNNB1 GNAS IGF2 NRAS PIK3CA
13
Show member pathways
12.49 BRAF CTNNB1 NRAS PIK3CA TP53
14
Show member pathways
12.47 BRAF NRAS PIK3CA TP53
15
Show member pathways
12.45 BRAF NRAS PIK3CA TP53
16 12.44 MIR195 MIR214 NRAS PIK3CA TP53
17
Show member pathways
12.38 BRAF CTNNB1 IGF2 NRAS PIK3CA
18
Show member pathways
12.34 CHEK2 CTNNB1 NRAS PIK3CA TP53
19 12.31 CHEK2 CTNNB1 NRAS PIK3CA TP53
20
Show member pathways
12.26 BRAF GNAS MC2R PIK3CA
21
Show member pathways
12.18 BRAF NRAS PIK3CA TP53
22
Show member pathways
12.18 BRAF CTNNB1 GNAS NRAS PIK3CA PRKAR1A
23 12.13 CHEK2 NRAS PIK3CA TP53
24
Show member pathways
12.13 BRAF NRAS PIK3CA TP53
25 12.11 BRAF CHEK2 CTNNB1 TP53
26
Show member pathways
12.09 GNAS NRAS PIK3CA PRKAR1A
27 11.99 BRAF NRAS PIK3CA TP53
28 11.98 BRAF CTNNB1 GNAS PRKAR1A TP53
29 11.92 CTNNB1 NRAS PIK3CA TP53
30 11.91 CTNNB1 NRAS PIK3CA TP53
31
Show member pathways
11.81 CYP11A1 CYP11B2 CYP17A1
32
Show member pathways
11.78 BRAF NRAS PIK3CA
33
Show member pathways
11.75 BRAF CTNNB1 GNAS PIK3CA PRKAR1A
34 11.74 BRAF CTNNB1 IGF2 NRAS PIK3CA TP53
35 11.72 BRAF NRAS TP53
36 11.7 BRAF CTNNB1 CYP11A1 GNAS
37 11.68 BRAF GNAS PIK3CA
38 11.67 BRAF GNAS IGF2 NRAS PRKAR1A
39 11.66 CHEK2 PIK3CA TP53
40
Show member pathways
11.66 CYP11A1 CYP11B2 CYP17A1
41 11.65 NRAS PIK3CA TP53
42
Show member pathways
11.63 BRAF CTNNB1 CYP11A1 CYP17A1 GNAS MC2R
43 11.6 BRAF GNAS NRAS
44 11.6 BRAF CTNNB1 IGF2 NRAS TP53
45 11.5 CYP11A1 CYP17A1 GNAS
46 11.31 BRAF GNAS NRAS PIK3CA PRKAR1A
47 10.99 BRAF GNAS PIK3CA
48 10.33 CHEK2 TP53

GO Terms for Adrenocortical Carcinoma, Hereditary

Cellular components related to Adrenocortical Carcinoma, Hereditary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.1 H19 MIR184 MIR195 MIR214 MIR503 MIR511

Biological processes related to Adrenocortical Carcinoma, Hereditary according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.73 H19 MIR184 MIR195 MIR214 MIR503 MIR511
2 cellular response to drug GO:0035690 9.61 BRAF CHEK2 TP53
3 steroid biosynthetic process GO:0006694 9.58 CYP11A1 CYP11B2 CYP17A1
4 positive regulation of connective tissue replacement GO:1905205 9.51 MIR195 MIR214
5 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.49 CHEK2 TP53
6 replicative senescence GO:0090399 9.48 CHEK2 TP53
7 C21-steroid hormone biosynthetic process GO:0006700 9.46 CYP11A1 CYP11B2
8 hair follicle placode formation GO:0060789 9.37 CTNNB1 GNAS
9 renal water homeostasis GO:0003091 9.33 CYP11B2 GNAS PRKAR1A
10 insulin receptor signaling pathway via phosphatidylinositol 3-kinase GO:0038028 9.32 IGF2 PIK3CA
11 sterol metabolic process GO:0016125 9.13 CYP11A1 CYP11B2 CYP17A1
12 glucocorticoid biosynthetic process GO:0006704 8.8 CYP11A1 CYP11B2 CYP17A1

Molecular functions related to Adrenocortical Carcinoma, Hereditary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 8.8 CYP11A1 CYP11B2 CYP17A1

Sources for Adrenocortical Carcinoma, Hereditary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....